| Etretinate Induced Cardiovascular Malformations in Mouse Embryo |
|
Il Kyung Kim1, Chang Sung Son2, Young Chang Dockgo2, Yong Hyuk Jeon3 |
1Department of Pediatrics, Seoul Adventist Hospital Seoul, Korea
2Department of Pediatrics, College of Medicine, Korea University, Seoul Korea
2Department of Pediatrics, College of Medicine, Korea University, Seoul Korea
3Department of Anatomy, College of Medicine, Korea University, Seoul Korea |
| Etretinate에 의해 유발되는 마우스 배자의 심혈관 기형 |
|
김일경1, 손창성2, 독고영창2, 전용혁3 |
1서울위생병원 소아과
2고려대학교 의과대학 소아과학교실
2고려대학교 의과대학 소아과학교실
3고려대학교 의과대학 해부학교실 |
|
|
|
|
| Abstract |
Purpose
: Etretinate(Tigason? is an aromatic retinoid currently in therapeutic use for psoriasis but studies have shown that it is a potent teratogen in human and in experimental animal. So we carried this study to observe teratogenic effects of etretinate and to search a possibility of etretinate for using as an experimental model to induce cardiovascular malformation.
Methods
: In order to determine the effect to etretinate on embryonic cardiovascular system, pregnant ICR mice were given intragastrically single doses of 50mg/kg or 100mg/kg of etretinate at day 8,9 or 10 of gestation.
Results
: All of the 172 treated surviving fetuses, showed extracardiac malformation. Extrecardiac malformations induced were largely craniofacial, limb, tail and thymic defects. Of the 172 treated surviving fetuses, 53(31%) showed cardiovascular anomalis. The highest cardiovascular malformation was induced by administration of 100mg/kg at day 8 of gestation(35/50, 70%), and the most common cardiovascular malformation was transposition of great arteries in the same group.(23/50, 46%)
Conclusion
: The results indicate that etretinate has a teratogenic effect on developing cardiovascular system and the type and incidence of cardiovascular abnormalities are largely dose and stage dependent. |
| Key Words:
Etretinate, Fetal mouse, Cardiac malformation |
|
Download Citation
